NASD · Healthcare · Biotechnology · USA
Summit Therapeutics Inc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Summit Therapeutics is a biopharmaceutical company developing medicinal therapies to improve quality of life and address serious unmet medical needs in oncology. The company's lead candidate is ivonescimab, a bispecific antibody combining immunotherapy and anti-angiogenesis effects. Summit is conducting Phase III clinical trials in non-small cell lung cancer and colorectal cancer across multiple regions.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Summit Therapeutics Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on SMMT yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.